Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Current Deferred Revenue (2018 - 2026)

Profound Medical has reported Current Deferred Revenue over the past 8 years, most recently at $445000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 6.21% year-over-year to $445000.0; the TTM value through Dec 2025 reached $445000.0, up 6.21%, while the annual FY2025 figure was $445000.0, 6.21% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $445000.0 at Profound Medical, up from $434000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $801000.0 in Q3 2024 and troughed at $11000.0 in Q2 2022.
  • A 5-year average of $351100.0 and a median of $315500.0 in 2023 define the central range for Current Deferred Revenue.
  • On a YoY basis, Current Deferred Revenue climbed as much as 57586.38% in 2021 and fell as far as 95.89% in 2021.
  • Year by year, Current Deferred Revenue stood at $477000.0 in 2021, then decreased by 1.26% to $471000.0 in 2022, then surged by 54.56% to $728000.0 in 2023, then tumbled by 42.45% to $419000.0 in 2024, then grew by 6.21% to $445000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for PROF at $445000.0 in Q4 2025, $434000.0 in Q3 2025, and $694000.0 in Q2 2025.